apogossypol

07/23/2009 - "Together with its improved chemical, plasma, and microsomal stability relative to compound 2 (apogossypol), compound 8r represents a promising drug lead for the development of novel apoptosis-based therapies for cancer."
04/01/2009 - "Together with its improved plasma and microsomal stability relative to Apogossypol, BI79D10 represents a lead compound for the development of novel apoptosis-based therapies for cancer."
06/01/2015 - "In addition, the in vivo study indicated that apogossypol significantly inhibited tumor growth in a dose‑dependent manner with reduced toxicity compared with gossypol. "
06/01/2015 - "Immunofluorescence was performed in order to detect the expression levels of apoptosis‑associated proteins in xenograft tumors following apogossypol treatment. "
03/15/2008 - "Taken together, these studies indicate that apogossypol is superior to parent compound gossypol with respect to toxicology and efficacy, suggesting that further development of this compound for cancer therapy is warranted."

05/01/2012 - "Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells."

06/01/2015 - "The aim of the present study was to investigate the growth inhibitory effects of apogossypol on prostate cancers in vitro and in vivo. "
01/01/2018 - "[Corrigendum] Inhibitory activity of apogossypol in human prostate cancer in vitro and in vivo."
06/01/2015 - "Inhibitory activity of apogossypol in human prostate cancer in vitro and in vivo."
06/01/2015 - "In conclusion, the present study indicated that apogossypol effectively inhibited the growth and proliferation of prostate cancer cells and may be a potential agent for prostate cancer therapy. "
01/01/2017 - "Correction for Dash et al., Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity."

07/23/2009 - "Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins."
05/27/2010 - "BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins."

07/23/2009 - "Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins."
05/27/2010 - "BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins."